181 publications
Name | Date | Type | Actions |
---|---|---|---|
2006 Financial Report Le chiffre d’affaires s’est accru de 7,6% par rapport à l’exercice précédent. |
04/06/2007 | Public releases | |
2008 annual earnings The Vétoquinol Board of Directors, meeting on March 20, 2009, reviewed the group’s business and approved the group’s 2008 financial statements. |
31/03/2009 | Public releases | |
2008 Interim Revenues increase by 5% Vétoquinol generated revenues of 116.7 million euros in the first half of 2008, a 5% increase over the 111.1 million euros |
22/07/2008 | Public releases | |
2008 revenue: €234.4 M Revenue grew in 2008, despite poor economic conditions in the second half and |
22/01/2009 | Public releases | |
2009 annual earnings March 31, 2010 – (Lure, France) – Vétoquinol’s Board of Directors, meeting on March 11, 2010, reviewed the Group’s business and approved its 2009 financial statements. |
31/03/2010 | Public releases | |
2009 Revenue improvement in trends in the first quarter Vétoquinol’s revenue for the first quarter of 2009 reached €57.1 M, an increase of 4.4% over the first quarter of 2008. |
09/04/2009 | Public releases | |
2010 annual earnings Lure (France), April 4, 2011 – Vétoquinol’s Board of Directors, meeting on March 18, 2011, has reviewed the Group’s business and approved its 2010 financial statements. |
04/04/2011 | Public releases | |
2010 Revenues grow 11.8%, driven by organic growth The Vétoquinol Group reports sustained sales growth driven by its “hybrid” business model, supported by a sound level of organic growth. |
25/01/2011 | Public releases | |
2011 annual earnings Lure (France), April 03, 2012 – The Vétoquinol Board Meeting of March 26, 2012 has reviewed the Group’s business and approved the 2011 financial statements. |
03/04/2012 | Public releases | |
2011, a year of transition Lure (France), January 24, 2012 – In 2011, Vétoquinol achieved sales of €284.1 million, 0.7% up on the previous year and stable on a like-for-like basis. |
24/01/2012 | Public releases | |
2012 sales up 5.0% Lure (France), January 24, 2013 – Vétoquinol posted 2012 sales of €298.3 million, up 5.0% compared to the previous year. At constant exchange rates, annual sales increased by 3.0%. |
24/01/2013 | Public releases | |
2012, return to growth Lure, March 26, 2013 – The Vétoquinol Board meeting of March 7, 2013 reviewed the Group's business and approved the 2012 financial statements. |
26/03/2013 | Public releases | |
2013 3rd quarter sales show organic growth Vétoquinol generated sales of €74.0 million in the 3rd quarter of 2013, a drop of 0.1% based on reported data, and a 4.4% increase at constant exchange rates. |
24/10/2013 | Public releases | |
2013 growth driven by reference products Lure (France), March 12, 2014 – At its March 11, 2014 meeting, the Vétoquinol SA board of directors reviewed the Group results and approved the 2013 financial statements. |
12/03/2014 | Public releases | |
2014 sales up 5.2% to €315.3 million The Vétoquinol Group posted 2014 sales of €315.3 million, up 5.2% from the previous year. At constant exchange rates, sales rose by 6.3%. The Vétoquinol Group achieved organic growth of 1.4% in 2014. |
22/01/2015 | Public releases | |
2015 results sales of reference products up 9.4% ebit up 10.3% At its meeting on March 18, 2016, the Vetoquinol S.A. Board of Directors reviewed the Group’s results and approved the 2015 financial statements. |
21/03/2016 | Public releases | |
2015 sales up 8.7% to €342.6 million The Vetoquinol Group posted 2015 sales of €342.6 million, up 8.7% on reported data and up 3.8% at constant exchange rates. The Group benefited from a positive currency impact of 4.9% mainly linked to the US dollar, Indian rupee and British pound. |
08/02/2016 | Public releases | |
2016 sales: €350.3 million 4.3% like-for-like growth The Vetoquinol Group posted sales of €350.3 million for 2016, representing like-for-like growth of 4.3%. After a negative currency impact of 2.0% mainly linked to the British pound, Canadian dollar and Indian rupee, reported growth amounted to 2.3%. |
26/01/2017 | Public releases | |
2017 sales: €352.2 million 7.6% like-for-like growth in essentials products The Vetoquinol Group posted sales of €352.2 million for the 2017 financial year, up 1.0% like-forlike. After a negative currency impact of 0.5%, mainly linked to the US and Canadian dollars, reported growth amounted to 0.5%. |
23/01/2018 | Public releases | |
2018 sales: up 3.2% to €367.9 million 9.1% GROWTH IN ESSENTIALS PRODUCTS AT CONSTANT EXCHANGE RATES
|
24/01/2019 | Public releases | |
2019 annual results: group sales €396.0M, up 6.1% at constant exchange rates. Net income group share: €28.6M (7.2% of sales) At its meeting on March 24, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2019 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon. |
26/03/2020 | Public releases | |
2019 sales: €396.0 million (Up 7.6%) The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates. |
23/01/2020 | Public releases | |
2020 annual results 2020 sales: €427.5m (up 8.0% as reported)
EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%)
Net income - Group share: €19.2m (4.5% of sales)
Cash flow: €92.2m
|
01/04/2021 | Public releases | |
2020 first half results consolidated sales: €196.1m (up 7.5% at constant exchange rates) net income group share: €15.1m (7.7% of sales) At its meeting on July 29, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the first half 2020 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon. |
30/07/2020 | Public releases | |
2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate) Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.” |
21/01/2021 | Public releases | |
2021 Annual results ALL FINANCIAL INDICATORS UP. |
24/03/2022 | Public releases | |
2021 first half results 2021 Half year results |
29/07/2021 | Public releases | |
2022 ANNUAL RESULTS Annual sales: €540m (up 3.6% as reported) |
23/03/2023 | Public releases | |
2022 HALF YEAR RESULTS Sales: €271m (up 6.0% as reported) |
15/09/2022 | Public releases | |
2022 HALF YEAR RESULTS Additional information on the Group’s strategy Following the conference call organised on 15 September 2022 to present its half-year results, Vetoquinol would like to provide some additional information on the strategy implemented and its outlook. |
23/09/2022 | Public releases , Half Year Report | |
2023 ANNUAL RESULTS Annual sales: €529m (stable at constant exchange rates) |
20/03/2024 | Public releases | |
2023 HALF-YEAR RESULTS Sales: €256m (-5.4% as reported) |
07/09/2023 | Public releases | |
3rd quarter revenues confirm promise of For the nine months ended September 30, 2007, Vétoquinol’s total revenues reached €166.0 M, an increase of 11.3% compared with the |
25/10/2007 | Public releases | |
7.8% organic growth in Q4 2013 The Vétoquinol Group posted Q4 2013 sales of €80.1 million, up +7.8% like for like from Q4 2012. |
23/01/2014 | Public releases | |
Activity Report 2006 |
04/06/2007 | Public releases | |
All key financial indicators up in 2016 At its meeting on March 22, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2016 financial statements. |
22/03/2017 | Public releases | |
Annual earnings for 2006: a year of good performance |
23/04/2007 | Public releases | |
Annual sales 2022 Total group Sales: €540 million (up 3.6% as reported) |
18/01/2023 | Public releases | |
Annual sales 2023: €529 million Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates) |
24/01/2024 | Public releases | |
Availability of the 2019 universal registration document Vetoquinol informs that it has filed its 2019 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 23, 2020. |
23/04/2020 | Public releases | |
Availability of the 2020 universal registration document Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021. |
28/04/2021 | Public releases | |
Availability of the 2021 universal registration document Vetoquinol informs that it has filed its 2021 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 22th, 2022. |
22/04/2022 | Public releases | |
Availability of the 2022 universal registration document On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
13/04/2023 | Public releases | |
Availability of the 2023 universal registration document On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
24/04/2024 | Public releases | |
BOREVE-D: Vétoquinol is participating in a project to raise awareness of the need to treat pain in cattle June 30, 2010 (Lure, France) – Vétoquinol, in collaboration with two other veterinary laboratories, is participating in a project organised by the Syndicat de l’Industrie du Médicament Vétérinaire (SIMV) to raise awareness of the need to treat pain in cattle. |
30/06/2010 | Public releases | |
Business is strong in first-half of 2007 : + 12.9% 2007 Half year Financial Report |
26/07/2007 | Public releases | |
Combined ordinary and extraordinary general meeting May 21, 2019 The Combined Ordinary and Extraordinary General Meeting of Vetoquinol shareholders was held on Tuesday May 21, 2019 in Lure, chaired by Etienne Frechin. |
22/05/2019 | Public releases | |
Combined ordinary and extraordinary general meeting May 29, 2018 The Combined Ordinary and Extraordinary General meeting was held on Tuesday May 29, 2018 in Lure, chaired by Etienne Frechin. |
29/05/2018 | Public releases | |
Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2015 (french) Le rapport financier semestriel relatif à l’exercice 2015 peut être consulté ou téléchargé sur les sites |
30/07/2015 | Public releases | |
Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2016 (french) Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2016 |
28/07/2016 | Public releases | |
Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2017 (french) Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2017 |
27/07/2017 | Public releases | |
Continued sales growth driven by sustained organic growth April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition. |
22/04/2010 | Public releases | |
Continued Sales Growth in the second Quarter of 2010 Vétoquinol recorded strong sales growth (+15.1%) in the first six months of 2010, driven mainly by an increase in organic growth. |
16/07/2010 | Public releases | |
Covid-19: Vetoquinol donates masks to neighboring healthcare facilities Vetoquinol S.A, the animal health laboratory based in Lure (70) has decided to donate more than 6000 masks to hospitals and associations in the region. This is a civic action to help, amongst others, hospitals in the Belfort Montbéliard, Vesoul and Saint-Rémy regions. |
20/03/2020 | Public releases | |
Departure of Pierre Konareff April 14, 2010 (Lure, France) – The Vétoquinol Group today announces the departure of Pierre |
14/04/2010 | Public releases | |
Dominique Derveaux appointed Group Chief Operations Officer
Effective April 1, 2020, Vetoquinol’s Board of Directors has appointed Dominique Derveaux Group Chief Operations Officer. In this capacity, he will run the Business, Marketing & Medical, Industrial, and Information Systems departments. He will report to Vetoquinol CEO Matthieu Frechin. |
28/04/2020 | Public releases | |
Double-digit growth in 2021 Total Group Sales: €521 million (up 21.9% as reported) |
20/01/2022 | Public releases | |
Dynamic first half 2016 2016 Half year Financial Report |
28/07/2016 | Public releases | |
Earnings for 2007 attest to strength of business growth model The Vétoquinol board of directors, meeting on February 22, 2008, reviewed the group’s business in 2007 and approved the related financial statements. In 2007, Vétoquinol once again achieved significant improvement in its key performance |
18/03/2008 | Public releases | |
European launch of new Nsaid Cimalgex® Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs. |
14/06/2011 | Public releases | |
First half 2015 sales €167.2m, up 11.9% The July 29, 2015 Vétoquinol SA Board of Directors meeting reviewed Group revenues and approved the H1 2015 financial statements. |
30/07/2015 | Public releases | |
First half 2018 results At its meeting on July 25, 2018, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2018 financial statements. |
26/07/2018 | Public releases | |
First half 2019 results At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements. |
25/07/2019 | Public releases | |
First nine months 2022 sales: €405M In line with year-end outlook |
12/10/2022 | Public releases | |
Flevox® the new parasiticide for dogs and cats Lure (France), 14 February 2012 – Vétoquinol launches Flevox®, the latest addition to its range of parasiticides. The new drug is based on fipronil, the molecule par excellence in the treatment of tick and flea infestations in pets. |
14/02/2012 | Public releases | |
Forcyl® - a booming brand Lure (France), November 14, 2012 – Vétoquinol receives a new indication for its Forcyl® product, designed for cattle, and a new market authorization for Forcyl® Swine for pigs. |
14/11/2012 | Public releases | |
Forcyl®: european launch of new drug Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection. |
29/09/2011 | Public releases | |
Growth in all financial indicators in 2018. Essentials products sales: €179.4M (up 9.1% at constant exchange rates). Net income group share €36.3M (up 4.0%) At its meeting on March 19, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2018 financial statements. |
20/03/2019 | Public releases | |
Growth in Revenues in the first half of 2009 Vétoquinol’s revenues in the first half of 2009 totalled EUR 119.9 million, an increase of 2.7% compared to the first half of the preceding year. |
16/07/2009 | Public releases | |
H1 2022 Sales H1 2022 Sales: €271m, up 6.1% |
20/07/2022 | Public releases | |
Information relative à un engagement du Conseil d’Administration pris au bénéfice du Directeur Général Délégué Groupe (french) Lors de sa réunion du 13 mars 2009, le Conseil d’Administration a pris l’engagement, dans le cadre de la loi du 21 août 2007, de verser une indemnité à Monsieur Dominique HENRYON, Directeur Général Délégué Groupe, en cas de révocation de ce dernier pour tout autre motif qu’une faute grave. Cette décision se substitue à celle du 1er décembre 1998. |
30/03/2009 | Public releases | |
Information relative au code de gouvernance Lors de la réunion du Conseil d’administration du 16 décembre 2014, les administrateurs ont adopté le code de gouvernance Middlenext. Depuis 2008, Vétoquinol se référait au code AFEP-MEDEF. |
20/12/2014 | Public releases | |
Information relative au Code de Gouvernance (french) Lors de la réunion du Conseil d’administration du 16 décembre 2014, les |
18/12/2014 | Public releases | |
International expansion and new product launches Lure (France), July 19, 2011 – Vétoquinol Group sales rose to €139.7 million in the first six months of 2011. |
19/07/2011 | Public releases | |
Jacques du Puy appointed Vétoquinol Managing Director Lure (France), October 12, 2011 – The Vétoquinol Group announces the appointment |
12/10/2011 | Public releases | |
Jean-Yves RAVINET appointed Group Chief Operating Officer Lure (France), January 7, 2014 – The Vétoquinol Group announces the appointment of Jean-Yves Ravinet as Group Chief Operating Officer. |
07/01/2014 | Public releases | |
KIBOW BIOTECH INC. et Vétoquinol S.A. étendent leur accord de commercialisation et de licence vétérinaire pour des applications mondiales (french) |
25/02/2008 | Public releases | |
Matthieu Frechin named Managing Director of Vétoquinol December 14, 2009 (Lure, France) – The Board of Directors of Vétoquinol, at its December 10 |
15/12/2009 | Public releases | |
Mis en oeuvre des recommandations AFEP/MEDEF du 6 octobre 2008 sur les rémunérations des dirigeants mandataires sociaux des sociétés cotées Lors de sa réunion du 5 décembre 2008, le Conseil d’administration a pris connaissance des recommandations AFEP-MEDEF du 8 octobre 2008 sur la rémunération des dirigeants sociaux des sociétés cotées. |
22/12/2008 | Public releases | |
Mise à disposition ou de consultation du rapport financier semestriel 2010 (french) Le Rapport financier semestriel 2010 de Vétoquinol peut être consulté ou téléchargé sur |
17/09/2010 | Public releases | |
Modalité de mise à disposition ou consultation du rapport annuel financier 2008 (french) Le Rapport annuel financier 2008, peut être consulté ou téléchargé |
04/05/2009 | Public releases | |
Net Sales rise 3% to €66.4 Million in the first Quarter of 2011 The Vétoquinol group reported a 3.0% rise in first quarter 2011 net sales to €66.4 million, compared to the same period last year. |
19/04/2011 | Public releases | |
Orion Animal Health and Vetoquinol expand collaboration - Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements. |
18/01/2021 | Public releases | |
Pierre Konareff est nommé Directeur Financier et Juridique du Groupe Vétoquinol (french) Vétoquinol annonce la nomination de Pierre Konareff au poste de Directeur Financier et Juridique du groupe. |
08/07/2008 | Public releases | |
Présentation des résultats 2006 de Vétoquinol (french) |
23/04/2007 | Public releases | |
Presentation of Vétoquinol’s results for the first half of 2007 2007 Half year results |
27/09/2007 | Public releases | |
Q1 2013 sales Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012. |
16/04/2013 | Public releases | |
Q1 2015 sales show solid growth at €81.3 million (up +11.0%) Vétoquinol posted first quarter 2015 sales of €81.3 million (after currency gains of €4.5 million), up +11.0%. At constant exchange rates, first quarter 2015 sales amounted to €76.7 million, a +4.8% increase from €73.2 million in Q1 2014. |
14/04/2015 | Public releases | |
Q1 2017 sales stable at €86.1 million Consolidated sales for Q1 2017 amounted to €86.1 million, up 0.4% as reported from the same period last year. Sales were boosted by a 1.8% positive currency impact mainly related to non-European currencies. Q1 sales fell 1.4% like-for-like. |
13/04/2017 | Public releases | |
Q1 2018 sales: €87.6M like-for-like growth up 5.6%, 0.4% as reported growth of essentials products: up 6.8% as reported Vetoquinol posted Q1 2018 consolidated sales of €87.6 million, up 5.6% like for like and 0.4% as reported, compared to the same period last year. Negative currency impacts of 5.2% were mainly related to the US and Canadian dollars and the Indian rupee. |
12/04/2018 | Public releases | |
Q1 2019 sales: €90.9 million (up 3.7%) Vetoquinol Group sales for Q1 2019 amounted to €90.9 million, up 2.3% at constant exchange rates and up 3.7% as reportedfrom the same period last year. |
17/04/2019 | Public releases | |
Q1 2020 sales €103.4 million (Up 13.7%) Vetoquinol Group sales for Q1 2020 amounted to €103.4 million, up 13.7% as reported and up 13.4% at constant exchange rates. |
16/04/2020 | Public releases | |
Q1 2021 sales Q1 2021 sales : €128M (up 28% at constant exchange rates, up 24% as reported)
Q1 2021 essential sales : €72.6M (up 38% at constant exchange rates, up 36% as reported)
|
15/04/2021 | Public releases | |
Q1 2022 SALES: €135M Q1 2022 SALES: €135M |
13/04/2022 | Public releases | |
Q1 2023 Sales: €145M Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates. |
20/04/2023 | Public releases | |
Q1 sales: €85.8M Vetoquinol posted Q1 2016 sales of €85.8 million, representing organic growth of 7.7%. Changes in exchange rates resulted in a negative currency impact of 2.1%; reported sales for the first three months of 2016 grew by 5.6%. |
19/04/2016 | Public releases | |
Q2 2013 sales Vétoquinol posted Q2 2013 sales of €70 million, up 0.3% on reported figures and up 1.4% like for like. |
16/07/2013 | Public releases | |
Q3 2011 Sales Vétoquinol achieved Q3 2011 sales of €68.4 million, in line with the previous year. |
25/10/2011 | Public releases | |
Q3 2014 sales up 11.0% The Vétoquinol Group reported Q3 2014 sales of €82.2 million, up 11.0% compared to the same period last year (up 11.1% at constant exchange rates). |
23/10/2014 | Public releases | |
Q3 2017 sales of €88.3 million, up 5.2% at constant exchange rates For the third quarter of 2017, the Vetoquinol Group posted sales of €88.3 million, up 5.2% from Q3 2016 at constant exchange rates. |
17/10/2017 | Public releases |